Answers are grounded in this paper and cite their sources.
Elevated intracellular labile ferrous iron is a hallmark of many cancers and can activate endoperoxide-containing molecules through Fenton chemistry. We developed a ferrous iron-activatable drug conjugate (FeADC) platform based on a 1,2,4,5-tetraoxane scaffold for tumor-selective drug delivery. Doxorubicin-loaded tetraoxane conjugates release their payload in the presence of Fe(II) via tandem endoperoxide reduction and retro-Michael elimination. These FeADCs exhibited potent antiproliferative activity across cancer cell lines with dysregulated iron metabolism while displaying markedly improved selectivity over doxorubicin in nontumorigenic cells. Fluorescence microscopy confirmed the efficient intracellular release of doxorubicin in HCT116 colorectal cancer cells. Moreover, in a colorectal cancer xenograft model, the tetraoxane conjugate achieved tumor growth inhibition comparable to that of doxorubicin administered at an equivalent dose. Collectively, these findings establish the 1,2,4,5-tetraoxane scaffold as a promising ferrous iron-responsive platform for tumor-activated prodrugs, enabling targeted drug release and potentially improving the therapeutic index of anticancer agents.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: